Bioenvision Pre-Clinical Studies Indicate "Abetafen" as a Potential Treatment of Benign & Malignant Prostate Diesease.LONDON--(BW HealthWire)--Aug. 26, 1999-- Bioenvision, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). : BIOV), a London-based biopharmaceutical company, today reported that pre-clinical studies of Abetafen, a derivative of Modrefen (Bioenvision's licensed product for breast cancer), suggest the compound could be efficient in the treatment of both benign and malignant prostate diesease. The pre-clinical results have enabled the company to commit to clinical trials and the development of the product. "We anticipate commencing clinical trials for Abetafen by the end of this year," said Dr. Christopher Dr. John R. Christopher, known popularly as "Dr. Christopher" was one of very few nationally prominent doctors of herbal medicine of the middle third of the 20th century, a "dark ages" of herbalism and was responsible for the herbal renaissance of the 1960s. Wood, Bioenvision's President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. . "Because its sister product Modrefen already has a product license, we expect that Abetafen will have an expedited path through the clinical trial process." Both Abetafen and Modrefen modulate To insert a data signal into a carrier wave or direct current. See modulation. the estrogen receptor estrogen receptor A protein of a superfamily of nuclear receptors for small hydrophilic ligands–eg, steroid hormones, thyroid hormone, vitamin D, retinoids; the presence of ERs in breast CA generally is associated with a better prognosis, as they respond to Beta (ERB) which is highly expressive in the prostate. Bioenvision also announced it has signed a licensing agreement with the School of Pharmacy at the University of Cardiff to develop two distinct groups of compounds. Both sets are designed to inhibit cancer cell growth and to promote tumor differentiation. The company plans an extensive pre-clinical program prior to clinical tests, which are expected to start within 18 months. Dr. Wood noted, "Bioenvision has a portfolio of 13 products, one of which has a product license, five of which are in clinical trials and seven of which are being prepared for clinical trials. We will also look to license further late stage oncology products that fit in with our development and marketing strategy." "Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. " statement under Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: This release contains forward-looking statements that are subject to risks and uncertainties, including, but not limited to, the impact of competitive products and pricing, product demand and market acceptance, reliance on key strategic alliances, fluctuations in operating results and other risk detailed from time to time in the company's filings with the Securities and Exchange Commission. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion